Upcoming Earnings Schedules, Quarterly Financial Results, Clinical Trial Results and Updates - Research Report on INSYS, Acorda, Spectrum Pharmaceuticals, XOMA, and Cambrex
NEW YORK, November 7, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting INSYS Therapeutics, Inc. (NASDAQ: INSY), Acorda Therapeutics, Inc. (NASDAQ: ACOR), Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), XOMA Corporation (NASDAQ: XOMA), and Cambrex Corporation (NYSE: CBM). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
INSYS Therapeutics, Inc. Research Report
On October 29, 2013, INSYS Therapeutics, Inc. (INSYS) announced that it will release its Q3 2013 results before the US markets open on Tuesday, November 12, 2013. INSYS reported that the conference call will be on the same day at 11:00 a.m. EST. The Company informed that the live audio webcast and replay of the call will be available at its website. The Full Research Report on INSYS Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Acorda Therapeutics, Inc. Research Report
On October 31, 2013, Acorda Therapeutics, Inc. (Acorda) released its Q3 2013 results. Acorda registered total revenues of $84.9 million in Q3 2013, up 9.7% YoY. The Company posted net income of $7.5 million in Q3 2013, compared to net income of $9.6 million in Q3 2012. Acorda reported diluted EPS of $0.18 in Q3 2013, compared to diluted EPS of $0.24 in Q3 2012. Commenting on the Company's progress, Ron Cohen, M.D., Acorda's President and CEO, said, "Pending agreement with FDA, we anticipate beginning a Phase 2b/3 study of a once-daily formulation of dalfampridine in post-stroke walking deficits in the second quarter of 2014. In addition, our Diazepam Nasal Spray NDA filing is on track for this year. Acorda now has six innovative products in clinical development, positioning us well for future growth."
The Full Research Report on Acorda Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Spectrum Pharmaceuticals, Inc. Research Report
On October 30, 2013, Spectrum Pharmaceuticals, Inc. (Spectrum Pharmaceuticals) announced the completion of enrollment for the pivotal trial of Captisol-enabled, propylene glycol-free (PG-free) high-dose melphalan as a conditioning treatment prior to autologous transplant for patients with multiple myeloma. Rajesh C. Shrotriya, MD, Chairman, CEO, and President of Spectrum Pharmaceuticals stated, "We are very pleased to have the patient enrollment completed ahead of schedule." Shrotriya continued, "Melphalan remains a high priority for Spectrum; if approved, Captisol-enabled melphalan would be the only drug approved as a conditioning agent for stem cell transplant in multiple myeloma. This product will also fit seamlessly into our existing commercial and research infrastructure." The Full Research Report on Spectrum Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
XOMA Corporation Research Report
On October 30, 2013, XOMA Corporation (XOMA) announced positive results from two Phase 2 clinical studies that are part of its broad gevokizumab proof-of-concept (POC) program. Commenting on the Erosive Osteoarthritis of the Hand Phase 2 POC Study, Paul Rubin Senior Vice President, Research and Development and Chief Medical Officer of XOMA, said, "Data from this trial has allowed us to determine that a pivotal study would require around 230 patients in each arm in order to achieve statistical significance at the same magnitude of effect we saw at three months. If the improvement in response trends we have observed continue, the six-month endpoint, which is the accepted primary endpoint for studies in arthritis, should require even fewer subjects per arm." Further, with regards to the Pyoderma Gangrenosum Pilot Study, John Varian, CEO of XOMA, commented, "Pyoderma gangrenosum is a serious, highly debilitating, very rare disease with limited therapeutic options and high unmet need. We initiated our POC trial based on discussions with FDA and a general understanding on the potential abbreviated path to approval for this indication. Based upon these early compelling results, we will discuss with the FDA the details for accelerated development with a single pivotal trial, typical in these types of rare diseases, to form the basis for a BLA filing." The Full Research Report on XOMA Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Cambrex Corporation Research Report
On November 1, 2013, Cambrex Corporation (Cambrex) released its Q3 2013 results. During the quarter, Cambrex registered net revenues of $77.5 million, up 30.4% YoY. The Company posted net income of $3.6 million, up 111.6% YoY, and diluted EPS of $0.12, up 100.0% YoY in Q3 2013. Reflecting on the quarter's performance, Steven M. Klosk, President and CEO of Cambrex, stated, "We are very pleased with our strong third quarter financial results and narrowed our full year guidance range, increasing the lower end of the range for both sales and EBITDA, reflecting our confidence in expected full year results." The Full Research Report on Cambrex Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to making mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner